Skip to main content

Advertisement

Log in

Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer

  • Review
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor monotherapy in germline BRCA1 and BRCA2 mutation-associated metastatic breast cancer is a well-tolerated and an effective therapeutic strategy, however, the durability of response can be limited. Checkpoint inhibitors targeting the PD-1/PD-L1 axis as monotherapy in metastatic triple-negative breast cancer (mTNBC) have a limited role due to low response rates, but are capable of long, durable responses. Combination PARP inhibition with checkpoint blockade is an emerging area of investigation with potential synergy to produce robust responses with durability. Mechanistically, PARP inhibition activates the stimulator of interferon gene (STING) pathway to promote dendritic cell and T lymphocyte recruitment, increases tumor neoantigens, and upregulates PD-L1 expression to increase the immunogenicity of the tumor and thereby potentially enhance responses to immunotherapy. Several clinical trials have reported early results on PARP inhibitor and PD-1/PD-L1 checkpoint inhibitor combinations. All studies have shown safety and tolerability of this combination regimen. In advanced breast cancer associated with a germline BRCA1 or BRCA2 mutation, response rates have been high and similar to what is observed with PARP inhibitor monotherapy. Additional follow-up is needed to see if combination with a checkpoint inhibitor can lead to a clinically meaningful extension of durability of response in patients with germline mutations in BRCA1 and BRCA2. In unselected mTNBC in the 1st–3rd line setting, response rates of combined PARP inhibitor and PD-1/PD-L1 inhibitors have ranged from 18–21%, with higher rates of response among those with alterations in homologous recombination DNA repair pathway genes. Multiple ongoing studies will report additional data on combinations of PARP inhibitors and checkpoint blockade in the future and this combination strategy remains an active area of investigation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

Availability of data and materials

Not applicable.

Code availability

Not applicable.

References

  1. Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363(20):1938–1948

    Article  CAS  Google Scholar 

  2. Dent R et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15 Pt 1):4429–4434

    Article  Google Scholar 

  3. Schmid P et al (2018) Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 379(22):2108–2121

    Article  CAS  Google Scholar 

  4. Robson M et al (2017) Olaparib for metastatic breast cancer in patients with a germline brca mutation. N Engl J Med 377(6):523–533

    Article  CAS  Google Scholar 

  5. Robson ME et al (2019) OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol 30(4):558–566

    Article  CAS  Google Scholar 

  6. Litton JK et al (2018) Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 379(8):753–763

    Article  CAS  Google Scholar 

  7. Litton JK et al (2020) Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol 31(11):1526–1535

    Article  CAS  Google Scholar 

  8. Cortes J et al (2020) Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396(10265):1817–1828

    Article  Google Scholar 

  9. Winer EP et al (2021) Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol 22(4):499–511

    Article  CAS  Google Scholar 

  10. Adams S et al (2019) Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort a of the phase II KEYNOTE-086 study. Ann Oncol 30(3):397–404

    Article  CAS  Google Scholar 

  11. Adams S et al (2019) Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol 30(3):405–411

    Article  CAS  Google Scholar 

  12. Emens LA et al (2019) Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol 5(1):74–82

    Article  Google Scholar 

  13. Kaelin WG (2005) The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 5(9):689–698

    Article  CAS  Google Scholar 

  14. Turner N, Tutt A, Ashworth A (2004) Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer 4(10):814–819

    Article  CAS  Google Scholar 

  15. Chabanon RM et al (2019) Beyond DNA repair: the novel immunological potential of PARP inhibitors. Mol Cell Oncol 6(2):1585170

    Google Scholar 

  16. Parkes EE et al (2017) Activation of STING-dependent innate immune signaling by s-phase-specific DNA damage in breast cancer. J Natl Cancer Inst 109:1

    Article  Google Scholar 

  17. Ablasser A et al (2013) cGAS produces a 2′–5′-linked cyclic dinucleotide second messenger that activates STING. Nature 498(7454):380–384

    Article  CAS  Google Scholar 

  18. Li A et al (2019) Prospects for combining immune checkpoint blockade with PARP inhibition. J Hematol Oncol 12(1):98

    Article  Google Scholar 

  19. Wang S et al (2018) Evaluation of niraparib in combination with anti-PD1/anti-PD-L1 in preclinical models [abstract]. Cancer Res. https://doi.org/10.1158/1538-7445.AM2018-1724

    Article  Google Scholar 

  20. Garcia-Diaz A et al (2019) Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep 29(11):3766

    Article  CAS  Google Scholar 

  21. Sato H et al (2017) DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat Commun 8(1):1751

    Article  Google Scholar 

  22. Vinayak S et al (2019) Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2019.1029

    Article  Google Scholar 

  23. Rugo H, Cussac A, Andre F (2020) 356TiP A phase II/III, open-label randomized trial of pembrolizumab + olaparib vs. pembrolizumab + chemotherapy after induction with pembrolizumab + chemotherapy in locally recurrent inoperable or metastatic triple-negative breast cancer: KEYLYNK-009. Ann Oncol. https://doi.org/10.1016/j.annonc.2020.08.458

    Article  Google Scholar 

  24. Yap T, Beck J, Stewart R (2018) JAVELIN PARP medley: a phase Ib/II study of avelumab (anti-PD-L1) plus talazoparib in locally advanced or metastatic solid tumors. Abstr Immun Cancer. https://doi.org/10.1093/annonc/mdy288.112

    Article  Google Scholar 

  25. Yap T et al (2019) Avelin parp medley, a phase 1b/2 study of avelumab plus talazoparib: results from advanced breast cancer cohorts [abstract]. In Proceedings of the 2019 san antonio breast cancer symposium. San Antonio. TX

  26. Domchek SM et al (2020) Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol 21(9):1155–1164

    Article  CAS  Google Scholar 

  27. Domchek S et al (2017) Abstract PD6–11: an open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): results in germline BRCA-mutated (gBRCAm) her2 negative metastatic breast cancer. Cancer Res. https://doi.org/10.1158/1538-7445.SABCS17-PD6-11

    Article  Google Scholar 

  28. Domchek S et al (2019) Phase II study of olaparib and durvalumab (MEDIOLA): updated results in patients with germline BRCA-mutated (mBRCAm) metastatic breast cancer. Ann Oncol. https://doi.org/10.1093/annonc/mdz253.017

    Article  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

Authors

Contributions

TG, SV, MT are equal contributors

Corresponding author

Correspondence to Tanya Gupta.

Ethics declarations

Conflicts of interest

SV served on the Advisory Board for Oncosec and received institutional funding for clinical trial research from Pfizer, Oncosec, and Seattle Genetics. MT reports research funding (to her institution) from AbbVie, AstraZeneca, Bayer, Biothera, Calithera, EMD Serono, Genentech, Merck, OncoSec Medical, Pfizer, PharmaMar, Tesaro and Vertex; an advisory role for AbbVie, Aduro, Blueprint Medicines, Celgene, Daiichi Sankyo, Genentech, Immunomedics, Lilly, Merck, Natera, OncoSec and Pfizer and DSMC membership for G1 Therapeutics and Immunomedics.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gupta, T., Vinayak, S. & Telli, M. Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer. Breast Cancer Res Treat 197, 51–56 (2023). https://doi.org/10.1007/s10549-022-06780-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-022-06780-4

Keywords

Navigation